The Chinese biopharmaceutical company, Sinovac, will allocate US$100 million for the construction of a vaccine production plant, which is part of a ten-year project that will begin in 2023. The project will start with the construction of a vaccine filling and packaging plant that will have a designed production capacity of 50 to 60 million doses per year.
Vice-president of Sinovac, Weining Meng, mentioned that the plan is to carry out the complete production cycle to establish the vaccine industry within ten years in order to benefit the Colombian nation. Flavia Santoro, president of ProColombia, the government agency in charge of promoting exports, international tourism, and foreign investment to support and advise companies in their international trade activities, said that they are pleased with the announcement of the Chinese company’s investment. This will contribute to the country’s pharmaceutical safety, job creation, technology transfer, and good manufacturing practices.
On the other hand, María Isabella Muñoz, executive director of Invest, an investment promotion agency for Bogota, mentioned that the city is currently recognized as one of the main pharmaceutical capitals in Latin America. The city concentrates 66% of drug manufacturers, 65% of drug wholesalers, and 49% of jobs in the industry.